

ABSTRACT

- 5       The present invention provides heregulin variants  
that are capable of binding an ErbB receptor. Included  
in the invention are variants of human heregulins, and,  
in particular, variants of human heregulin- $\beta$ 1 having  
enhanced affinity for the ErbB-3 and ErbB-4 receptors.
10. These variants include at least one amino acid  
substitution and can include further modifications.  
The invention also provides nucleic acid molecules  
encoding heregulin variants and related vectors, host  
cells, pharmaceutical compositions, and methods.